CIK 0001743881 · Large accelerated filer
BridgeBio Pharma, Inc.
Sign in to watch- Ticker
- BBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (650) 391-9740
- Business address
- 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304
- Former names
- BridgeBio Pharma LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,563,798
- in 3 filings, $4.6M under 10b5-1 plans
Net −$4,563,798. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-16 | Kumar Neil Chief Executive Officer | Shares withheld for taxes 10b5-1 | −32,854 | $33.84 | $1.1M | 243,560 |
| 2025-05-16 | Kumar Neil Chief Executive Officer | Option exercise · Restricted Stock Units 10b5-1 | −33,544 | 234,808 | ||
| 2025-05-16 | Kumar Neil Chief Executive Officer | Option exercise · Restricted Stock Units 10b5-1 | −19,599 | 215,592 | ||
| 2025-05-16 | Kumar Neil Chief Executive Officer | Option exercise · Restricted Stock Units 10b5-1 | −11,553 | 173,307 | ||
| 2025-05-16 | Trimarchi Thomas President and CFO | Shares withheld for taxes | −21,317 | $33.84 | $721K | 501,988 |
| 2025-05-16 | Apuli Maricel Chief Accounting Officer | Shares withheld for taxes | −4,780 | $33.84 | $162K | 142,859 |
| 2025-05-12 | KKR Genetic Disorder L.P. 10% owner | Sale | −6,000,000 | $34.20 | $205.2M | 13,260,971 |
| 2025-03-05 | KKR Genetic Disorder L.P. 10% owner | Sale | −6,000,000 | $32.96 | $197.8M | 19,260,971 |
| 2024-09-13 | KKR Genetic Disorder L.P. 10% owner | Sale | −5,800,000 | $25.75 | $149.3M | 25,260,971 |
| 2021-12-29 | Valantine Hannah Director | Purchase | +1,752 | $14.24 | $25K | 3,294 |
| 2021-12-28 | Valantine Hannah Director | Purchase | +1,542 | $12.68 | $20K | 1,542 |
| 2021-12-28 | Valantine Hannah Director | Purchase | +796 | $13.16 | $10K | 2,687 |
| 2021-02-17 | KKR Genetic Disorder L.P. 10% owner | Sale | −3,450,000 | $60.47 | $208.6M | 31,060,971 |
| 2020-05-28 | KKR Genetic Disorder L.P. 10% owner | Sale | −2,389,690 | $33.39 | $79.8M | 34,510,971 |
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion | +34,253,561 | 34,253,561 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Purchase | +2,647,100 | $17.00 | $45.0M | 36,900,661 |
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series B Preferred Units | −81,022,727 | 0 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series C Preferred Units | −36,246,893 | 0 | ||
| 2019-07-01 | KKR Genetic Disorder L.P. 10% owner | Conversion · Series D Preferred Units | −50,446,451 | 0 |
Page 19 of 19 · 379 trades